Form 4 for BIVI BIOVIE INC.
Accepted 2025-01-07 00:00:00 ET · period of report 2024-11-20 · accession 0001520138-25-000026 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-07 | 2024-11-20 | BIVI | ROGICH SIGMUND | Dir | A - Grant | $0.00 | +32.7K | 36.9K | +774% | $0 |
| D | 2025-01-07 | 2024-12-20 | BIVI | ROGICH SIGMUND | Dir | A - Grant | $0.00 | +22.1K | 22.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-20 | A | A | 32,700 | $0.00 | 36,926 | D | — | — | (F1) Represents a restricted stock unit ("RSU") grant, which was approved by the compensation committee of the issuer's board of directors, subject to board approval, which was obtained on November 20, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vest in four equal installments on February 8, 2025, May 8, 2025, August 8, 2025 and the earlier of November 8, 2025 and the date of the issuer's 2025 annual shareholders' meeting. |
| 2 | Derivative | Stock Option (right to buy) | 2024-12-20 | A | A | 22,070 | $0.00 | 22,070 | D | $1.90 · — to 2029-12-20 | 22,070 Common Stock | (F2) The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026. |